FDA Grants Breakthrough Therapy Designation for Acalabrutinib

August 1, 2017 – Today the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for acalabrutinib for the treatment of people with mantle cell lymphoma (MCL) who have received at least one prior therapy

While this news is for folks with mantle cell lymphoma, a cousin cancer to CLL, this is not an usual path to broader ultimate approval of a new medication.

Also, once a medication is approved, it can be used for any indication. though such “off label” insurance coverage can be a challenge

Overall, very good news

Read more: https://www.astrazeneca-us.com/media/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-08012017.html

The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
August 15, 2019

Shuttering of the Biden Cancer Initiative
August 5, 2019

Approval of a biosimilar for Rituximab
July 29, 2019

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)
May 29, 2019

May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
May 20, 2019

FDA places a partial hold on all venetoclax clinical trials for multiple myeloma (MM) patients
March 20, 2019